Comparison of Tamsulosin Versus Silodosin for Treatment of Patients with Benign Prostatic Hyperplasia

Objective: To evaluate the efficacy of drug in improving lower urinary tract symptoms for improved health care and better management patients. Study Design: Randomized controlled trial Place Duration Study: Department Urology, General Medicine Surgery, Pakistan Ordinance Factories Hospital, Wah Cantt from 1st January 2021 to 31st July 2022. Methodology: One hundred patients, age more than 45 years, moderate severe prostate hyperplasia prostrate size >50 gm were included. Detailes demographics recorded after taking informed written consent. Patients divided into two groups randomly through lottery method. In group A; patients given tablet Tamsulosin 0.4 mg once daily B; Silodosin 4 12 weeks. Effectiveness between both compared. Results: A, mean 59.70±7.45 years. 59.74±7.69 pre-treatment IPSS score 16.74±1.78 while was 16.12±2.46. Pre-treatment PVR A 57.62±8.9 B 57.96±8.71. The post-treatment showed that 9.26±1.61 had 6.58±1.26 P<0001. volume results 29.5±3.03 25.12±1.94 Conclusion: silodosin is an effective therapy LUTS men with benign prostatic hyperplasia. Keywords: Treatment, Benign hyperplasia, Lower